Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads scans and slides to outsmart stomach cancer

NCT ID NCT07454967

Diagnosis Sponsor: Qun Zhao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This study tested an artificial intelligence model that combines CT scans, digital pathology images, and patient history to improve diagnosis and risk prediction for gastrointestinal stromal tumors (GISTs). Researchers enrolled 300 patients with suspected stomach tumors. The AI aims to tell GISTs apart from other tumors, predict how aggressive they are, and guess genetic mutations—all without needing surgery. The results were compared to standard lab tests, but the AI's predictions were not shared with doctors, so it did not affect patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multimodal AI Analysis System (GIST-RadPath-AI Model)
What this could lead to
If successful, this AI could help doctors diagnose GISTs more accurately without invasive surgery and predict tumor risk and genetic mutations to guide treatment.
What could go wrong
This is an early observational study with 300 participants, so the AI may not work as well in larger or more diverse groups. The results are blinded and not used in patient care, so real-world benefits are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Started

Mar 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting with gastric submucosal tumors (SMTs) who are admitted to the Department of Gastrointestinal Surgery at The Fourth Hospital of Hebei Medical University for surgical or endoscopic treatment. The cohort includes patients with subsequently pathologically confirmed GISTs and other mesenchymal tumors (e.g., leiomyoma, schwannoma).

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Age ≥ 18 years, gender not limited. Clinical diagnosis of gastric submucosal tumor (SMT) or suspected gastrointestinal stromal tumor (GIST) based on gastroscopy or ultrasound. Scheduled for surgical resection or endoscopic biopsy at the study center. Standard preoperative contrast-enhanced CT scans are available (performed within 2 weeks prior to surgery). Patients or their legal guardians have signed the informed consent form. Exclusion Criteria: Received neoadjuvant therapy (e.g., Imatinib, chemotherapy, or radiotherapy) prior to surgery/biopsy. Poor quality of CT images (e.g., severe motion artifacts) affecting radiomics analysis. Insufficient tissue samples for pathological diagnosis or genetic testing. Confirmed diagnosis of other primary malignancies. Incomplete clinical data or lost to follow-up immediately after surgery.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Artificial intelligence (AI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric leiomyoma gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Artificial intelligence (AI) Gastric leiomyoma Gastric subepithelial tumors Gastrointestinal stromal tumors Multimodal imaging

Contacts and locations

Locations

  • Baoding Central Hospital

    Baoding, Hebei, 071030, China

  • Cangzhou People's Hospital

    Cangzhou, Hebei, 061000, China

  • Hengshui People's Hospital

    Hengshui, Hebei, 053099, China

  • Jinling Hospital

    Nanjing, Jiangsu, 210002, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430065, China

  • Shijiazhuang People's Hospital

    Shijiazhuang, Hebei, 050011, China

  • The Fifth Affiliated Hospital of Anhui Medical University

    Fuyang, Anhui, 236003, China

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, 421001, China

  • The Second Affiliated Hospital of Xingtai Medical College

    Xingtai, Hebei, 054000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.